Rezolute (RZLT) Stock Price, News & Analysis

Company Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $8.02 to $8.70
• 50-Day Range: $5.11 to $8.20
• 52-Week Range: $2.21 to $8.81
• Volume: 966,767 shs
• Average Volume: 957,275 shs
• Market Capitalization: $766.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Buy

Rezolute Stock Analysis - MarketRank™

Rezolute scored higher than 67% of companies evaluated by MarketBeat, and ranked 322nd out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Rezolute has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Rezolute has a consensus price target of $14.50, representing about 68.8% upside from its current price of $8.59.

Amount of Analyst Coverage

Rezolute has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rezolute are expected to decrease in the coming year, from ($0.93) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rezolute is -8.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rezolute is -8.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rezolute has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.45% of the float of Rezolute has been sold short.

Short Interest Ratio / Days to Cover

Rezolute has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rezolute does not currently pay a dividend.

Dividend Growth

Rezolute does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.45% of the float of Rezolute has been sold short.

Short Interest Ratio / Days to Cover

Rezolute has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.62

News Sentiment

Rezolute has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Rezolute this week, compared to 4 articles on an average week.

Search Interest

15 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

8 people have added Rezolute to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $31,200.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

18.39% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RZLT Stock Analysis - Frequently Asked Questions

How have RZLT shares performed this year?

Rezolute's stock was trading at $4.90 at the beginning of the year. Since then, RZLT stock has increased by 75.3% and is now trading at $8.59.

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) released its quarterly earnings data on Wednesday, September, 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.03.

Who are Rezolute's major shareholders?

Top institutional shareholders of Rezolute include Federated Hermes Inc. (16.13%), Marshall Wace LLP (3.32%), Nantahala Capital Management LLC (2.63%) and Affinity Asset Advisors LLC (2.53%). Insiders that own company stock include Young-Jin Kim, Daron Evans, Nevan C Elam, Nevan C Elam, Wladimir Hogenhuis, Wladimir Hogenhuis, Nerissa Kreher and Brian Kenneth Roberts.
View institutional ownership trends.

How do I buy shares of Rezolute?

Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rezolute own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Vanguard S&P 500 ETF (VOO).

Company Calendar

• Last Earnings: 9/17/2025
• Today: 9/23/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RZLT
• CIK: 1509261
• Web: www.rezolutebio.com
• Phone: (650) 206-4507
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rezolute: $14.50
• High Price Target: $20.00
• Low Price Target: $9.00
• Potential Upside/Downside: +78.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -65.03%
• Return on Assets: -58.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.37
• Quick Ratio: 14.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 4.38

Miscellaneous

• Outstanding Shares: 90,810,000
• Free Float: 74,111,000
• Market Cap: $739.19 million
• Optionable: Optionable
• Beta: 0.02